Abstract: The invention described herein pertains to the treatment of multiple sclerosis. In particular, the invention described herein pertains to the treatment of multiple sclerosis using compounds that modulate the action of acrolein.

Abstract: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.

Abstract: A liquid crystalline compound shown by the following formula (I). wherein R1 to R13 represent a hydrogen atom, a fluorine atom, a methyl group, a trifluoromethoxy group, or a cyano group, X represents —O—, —O—CO—, or the like, n is 0 or 1, and R14 represents -A-CO—CH?CH2, wherein A is a linking group. The liquid crystalline compound has a higher liquid crystal phase upper limit temperature, is chemically stable, can be inexpensively produced, and exhibits a large selective reflection wavelength zone ?? (a large ?n). A liquid crystalline composition comprising the liquid crystalline compounds, an optical film having a liquid crystal layer formed using the liquid crystalline composition, and an optical laminate comprising a substrate, an alignment film formed on the substrate, a liquid crystal layer formed using the liquid crystalline composition on the alignment film are also disclosed.

Abstract: The present invention relates to compounds suitable for modulating huntingtin protein processing and useful for treating or preventing huntingtin-related disorders. The invention provides pharmaceutical compositions comprising said compounds and methods of syntheses thereof.

Abstract: The present invention concerns an agent for prevention and treatment of pityriasis. The agent according to the present invention comprises at least one transaminase inhibitor effectively inhibiting the transamination process which is of pathogenetic relevance for the disease, prevents a recurrence of the disease and which protects the human skin flora. Upon release into the environment, no resistances are induced in other fungi.

Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.

Abstract: A liquid crystalline compound shown by the following formula (I). wherein R1 to R13 represent a hydrogen atom, a fluorine atom, a methyl group, a trifluoromethoxy group, or a cyano group, X represents —O—, —O—CO—, or the like, n is 0 or 1, and R14 represents -A-CO—CH?CH2, wherein A is a linking group. The liquid crystalline compound has a higher liquid crystal phase upper limit temperature, is chemically stable, can be inexpensively produced, and exhibits a large selective reflection wavelength zone ?? (a large ?n). A liquid crystalline composition comprising the liquid crystalline compounds, an optical film having a liquid crystal layer formed using the liquid crystalline composition, and an optical laminate comprising a substrate, an alignment film formed on the substrate, a liquid crystal layer formed using the liquid crystalline composition on the alignment film are also disclosed.

Abstract: A process for preparing pesticides or pesticidal intermediates, particularly 5-amino-1 aryl-3-cyanopyrazoles, having the formula said process comprising reacting a compound having the formula with a cyanide salt.

Abstract: The present invention provides a new process for the preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride, wherein this compound is prepared directly from the chloromethylalcohol. Importantly, the process of the present invention results in higher yields of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride without sacrificing its purity. The processes of the present inventin can be used to prepare not only the 2S,3S-derivative, but also the 2R,3S-, 2S,2R- and the 2R,3R-derivatives.

Abstract: Process for producing a nitroetheneamine derivative or its stereoisomer, its tautomer or a salt thereof comprising reacting a compound of the formula with a compound of the formula R6—CH2NO2 to obtain a compound of the formula and reacting the resulting compound with a compound of the formula

Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. Preferred (R)-Chiral 1-Subsbitutedamino-(n+1)-Alkanol compounds are substituted (R)-Chiral N-phenoxy N-phenyl aminoalcohols.

Abstract: A method for making an indole compound includes transition metal-catalyzed arylation of a hydrazone to form an aryl hydrazone, hydrolysis of the aryl hydrazone to form an aryl hydrazine, and acid catalyzed cyclization of the aryl hydrazine to form the indole compound.

Abstract: A medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): wherein the substituents are as defined in the disclosure, its stereoisomers, its tautomers or a salt thereof.

Abstract: A production method of hydrazine derivative having a group of the formula (II) which comprises subjecting a hydrazone derivative having a group of the formula (I) to catalytic reduction and deactivating the reduction catalyst contained in the reaction mixture thereof.

Abstract: There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl,R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl,R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, andR.sub.6, independently of R.sub.1, is lower alkoxycarbonyl,or salts thereof, provided that at least one salt-forming group is present.The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS.

Abstract: The present invention is directed to novel N.sup.1 -propargylhydrazines, N.sup.2 -propargylhydrazines and their salts in pharmaceutical compositions. The compounds according to the present invention have at least one of the following activities: monoamine oxidase-A inhibiting, monoamine oxidase-B inhibiting, anti-depressant, anti-anxiety and neuroprotectant activities. These compounds are useful as monoamine oxidase inhibitors and should be useful for the treatment of depression, anxiety and of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

Abstract: The invention relates to compounds of the formula: ##STR1## Compounds of the above formula have a great affinity for the neurotensin receptors.

Abstract: This invention relates to intermediate compounds which are useful for making substituted 1-phenyl-3-pyrazolecarboxamides. The compounds of the invention have the formula: ##STR1## in which: R'.sub.2 and R'.sub.3 each independently represent a hydrogen, a (C.sub.1 -C.sub.6)alkyl, a (C.sub.3 -C.sub.8)cycloalkyl, a (C.sub.3 -C.sub.8)cycloalkylmethyl;or R'.sub.2 and R'.sub.3 together constitute a trimethylene, tetramethylene or pentamethylene group;R.sub.y is at position 4 or at position 5 and represents a group chosen from: cyano, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, benzyloxycarbonyl, sulpho, (C.sub.1 -C.sub.4)alkylsulphonylamino, (C.sub.1 -C.sub.4)alkylphenylsulphonylamino, carbamoyl, (C.sub.1 -C.sub.4)alkylcarboxamido; on condition that R'.sub.2 and R'.sub.3 do not simultaneously represent hydrogen and on condition that R'.sub.2 is other than methyl when R.sub.y is a sulpho group. The salts of the above compounds are also part of the invention.

Abstract: A hydrazide compound represented by the following formula (I), and a silver halide photographic photonsensitive material comprising the hydrazide compound:A--(B).sub.b (I)wherein A represents a heterocyclic group, a condensed polycyclic aromatic group or a group formed by connecting at least two aromatic groups to each other, B represents a group represented by the following formula (I-B) or (II-B), and b represents an integer from 2 to 6;--L.sub.1 --Ar.sub.1 --NHNH--G.sub.1 --R.sub.1 (I-B)--L.sub.3 --Ar.sub.3 --L.sub.2 --Ar.sub.2 --NHNH --G.sub.2 --R.sub.2(II-B)wherein each of G.sub.1 and G.sub.2 represents a carbonyl group, an oxalyl group, a sulfonyl group or a phosphoryl group; each of R.sub.1 and R.sub.2 represents a hydrogen atom or a blocking group; each of Ar.sub.1, Ar.sub.2 and Ar.sub.3 represents an aromatic group or an aromatic heterocyclic group; and each of L.sub.1, L.sub.2 and L.sub.3 represents a linkage group.

Abstract: The invention relates to compounds having the general formula I ##STR1## where A if required can contain a functional and/or activated group C for coupling to selectively concentrating compounds or can contain a selectively concentrating compound coupled via the group C. B and B' are functional groups for coordinate bonding of groups carrying metal ions. The novel compounds are for forming complexes with radioactive metal ions, more particularly rhenium and technetium isotopes, and are used in medical diagnosis and therapy.

Abstract: Novel 2-(3-phenylpropyl)hydrazines, intermediates in and processes for the preparation thereof, and a method of treating personality disorders utilizing compounds or compositions thereof are disclosed.

Abstract: A process for the preparation of a 3-amino-2-(het)aroyl-acrylic acid derivative fo the formula ##STR1## in which Y represents a nitrile, or an ester group, --COOR.sub.1, or an acetyl group, whereR.sup.1 denotes C.sub.1 -C.sub.4 -alkyl, andR denotes optionally substituted alkyl, cyclopropyl, alkoxy, phenyl or amino,A represents nitrogen or C--R.sub.2, whereR.sub.2 denotes hydrogen, methyl, halogen, nitro, methoxy or cyano,X.sub.1 and X.sub.2 are identical or different and denote halogen, andX.sub.3 denotes hydrogen, halogen or nitro andX.sub.4 denotes halogen, nitro, methoxy or methylthio, which comprises reacting a 3-dialkylamino-2-(het)aroyl-acrylic acid derivative of the formula ##STR2## in which R.sub.3 and R.sub.4 are the same or different and represent an alkyl group having 1 to 4 carbon atoms, or, together with the nitrogen atom to which they are bonded, form a ring,with a primary amine of the formula R--NH.sub.2 in the presence of at least one equivalent of an acid HX in a solvent or in excess acid.

Abstract: Described herein is an isocyanate-reactive compound containing at least one linkage of the formula:--X--X--wherein X is independently in each occurrence --NR--, --S--, or --O--; R is independently in each occurrence hydrogen, C.sub.1-10 alkyl, aryl, or arylene; and at least one N, S, or O atom of the above formula is bonded to an aryl or arylene group. Also disclosed are isocyanate-reactive compositions containing the above compound and flexible polyurethane foams prepared therefrom.

Abstract: This application relates to a process for preparing alkylhydrazines from an alkene and hydrazine with an acid catalyst. More particularly, it relates to a process for preparing t-butylhydrazine from hydrazine and isobutylene in aqueous acid.

Abstract: 1-[2-(2,4-Dichlorophenyl)-pentyl]-1H-1,2,4-triazole can be produced, in a novel, simple, economical and isomer-free form, by reacting 2-(2,4-dichlorophenyl)-valeronitrile, in the presence of hydrogen, an acid and a hydrogenation catalyst, with a compound H.sub.2 N--NH--R to a compound of the formula ##STR1## hydrogenating the compound (III) catalytically to a compound ##STR2## hydrolysing compounds (IV) wherein R is not hydrogen, and converting the compounds (IV) wherein R=H, or salts thereof, with formamide and/or [3-(dimethylamino)-2-azaprop-2-en-1-ylidene]-dimethylammonium chloride, into 1-[2-(2,4-dichlorophenyl)-pentyl]-1H-1,2,4-triazole, or converting compounds (IV) wherein R=--COR', with aqueous formic acid, into the corresponding N,N'-bisformyl derivatives, and reacting these with formamide, optionally in the presence of NH.sub.3, to 1-[2-(2,4-dichlorophenyl)-pentyl]-1H-1,2,4-triazole. R in the formulae is hydrogen, --CHO, --COR', --COOR' or --CONH.sub.2, and R' is C.sub.1 -C.sub.

Abstract: This invention relates to substituted-1,3,4-benzotriazepines of the formula ##STR1## wherein X and Y are each independently hydrogen, lower alkyl, halogen, lower alkoxy, nitro and hydroxyl; R.sub.1 and R.sub.3 are each independently hydrogen or alkyl; R.sub.2 is hydrogen, lower alkyl, cycloalkyl lower alkyl, phenyl, Ar lower alkyl, hydroxyl and sulfhydryl; m and n are each independently integers of 0 or 1 and when m is 0, n is 1 and vice-versa; and p and q are independently integers of 1 or 2. Also included in the invention are the substituted-1,3,4-benzotriazepine derivatives of tautomeric form when the substituent for R.sub.1 and/or R.sub.3 in the above formula is hydrogen. The compound of this invention may be used as antihypertensive agents.

Abstract: The present invention provides novel substituted heptadeca-5,9- and 5,10-dienoic acid and similar fatty acid compounds which are derivatives of certain prostaglandins and are potent thromboxane A.sub.2 inhibitors. By virtue of this pharmacological property, they represent useful pharmacological agents for a wide variety of purposes.

Abstract: A process is disclosed for preparing anhydrous hydrazines by reacting a tertiary hydrazinium halide with a corresponding alkali metal or alkaline earth metal amide in the presence of a non-aqueous inert carrier.